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Background
Preservation of IL-17 producing CD4 + T (Th17) cell pop-
ulations may be beneficial in HIV-1 disease. Despite
broad interest in the role of Th17 cells in regulating
human immune responses little is known about the
manipulation of IL-17 in humans in vivo. IL-2 has been
used in conjunction with antiretrovirals to increase CD4+
T-cell counts in HIV-1, and is approved in some European
countries for this purpose. We sought to gauge the effects
of IL-2 administration on IL-17 production and inflam-
matory T cell responses among recently HIV infected per-
sons who had achieved virologic suppression on an anti-
retroviral regimen.
Methods
We randomized persons to receive or not receive a course
of IL-2 over 1 year and measured by flow cytometry T cell
responses to polyclonal and viral peptide specific stimula-
tion, T regulatory populations (T-reg, CD3+CD4+CD25+/
CD127-FoxP3+) T cell activation (CD38/HLA-DR) and
changes in maturation profiles of T cells (CD27, CD28,
CD45RA).
Results
Those who received IL-2 showed a significantly greater
expansion of CD4+ T cells and T-regs compared with par-
ticipants who did not receive IL-2. Counts of Th17 cells
did not change in response to IL-2 administration. The
degree of expansion in T-regs was significantly associated
with the degree of drop in inflammatory T cell responses,
a relationship which was independent of T cell activation.
We observed that administration of IL-2 mediated: an
expansion of T-regs, that was not associated with a change
in Th17 cells; expanded naive CD4+ T cells; and a selective
decline in HIV-1 Gag-specific T cell IFN-γ responses in par-
ticipants that received IL-2.
Conclusion
Our data suggests IL-2 limits production of but does not
reverse Th17 cells in humans and to achieve a state of
increased CD4+ T cell IL-17 expression additional
immune based in vivo interventions will need to be eval-
uated.
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